The European Society for Medical Oncology (ESMO) is pleased to announce the publication of the latest version of the scale that measures the clinical benefit of cancer treatments, the ESMO-MCBS ...

Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery ...

Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...